Intervention not reported
Chemobased OS ‐ 5‐FU based chemotherapy OS · patients with resectable gastric cancer
The intervention probably leads to lower chemobased OS ‐ 5‐FU based chemotherapy OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased OS ‐ Platinum‐based chemotherapy OS · patients with resectable gastric cancer
The intervention showed no clear difference in chemobased OS ‐ Platinum‐based chemotherapy OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased DFS ‐ 5‐FU based chemotherapy DFS · patients with resectable gastric cancer
The intervention probably leads to lower chemobased DFS ‐ 5‐FU based chemotherapy DFS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased DFS ‐ Platinum‐based chemotherapy DFS · patients with resectable gastric cancer
The intervention showed no clear difference in chemobased DFS ‐ Platinum‐based chemotherapy DFS (moderate certainty).
1 finding from 1 review
Altered fractionation radiotherapy plus chemotherapy vs Chemoradiotherapy with standard (conventional) fractionation
Outcome not reported · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
The review found no eligible studies for this question.
1 finding from 1 review
Death (all causes)
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to death due to any cause (absolute effect size estimates based… compared with ADT only (moderate certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher grade III to V adverse events compared with ADT only (low certainty).
1 finding from 1 review
Prostate cancer‐specific death5
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower prostate cancer‐specific death5 compared with ADT only (moderate certainty).
1 finding from 1 review
Time to progression
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to progression (absolute effect size estimates based on… compared with ADT only (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher discontinuation due to adverse events compared with ADT only (low certainty).
1 finding from 1 review
All adverse events
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher all adverse events compared with ADT only (low certainty).
1 finding from 1 review
Quality of life at 12 months (
1 finding from 1 review
Interruptions to cancer treatment (chemotherapy delays/discontinuations) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (chemotherapy… compared with placebo; GRADE not reported.
1 finding from 1 review
Intervention not reported
Chemotherapy toxicity · Adults with recurrent GBM
1 finding from 1 review
Intervention not reported
Chemotherapy toxicity During 1st 12 weeks of treatment · Adults with recurrent HGG
1 finding from 1 review
Long‐term mortality (binary outcome) All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (binary): definitive chemoradiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
1 finding from 1 review
Long‐term mortality (time‐to‐event outcome): chemoradiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
It is very uncertain whether non‐surgical changes long‐term mortality (time‐to‐event): definitive chemoradiotherapy… compared with surgical treatment of oesophageal cancer (primary outcomes) (very low certainty).
1 finding from 1 review
Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate < 80 ml/... · patients with high‐risk neuroblastoma
1 finding from 1 review
Intervention not reported
the toxic and side effects in digestive system after chemotherapy (no special data in trial of Zhang 2006) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects in digestive system after chemotherapy… (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects in digestive system after chemotherapy · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects in digestive system after chemotherapy (very low certainty).
1 finding from 1 review